Advancing artificial intelligence to eliminate trial and error in medicine.

DCVC

DCVC Bio

Alumni Ventures

Eisai

EPIC Ventures

Mubadala Capital Ventures

Insight Partners

Parkway Venture Capital

Radical Ventures

Wittington Ventures

Unlearn.AI

What's the formula for innovation?

🚀 First adopter ⇒ 👀 first follower ⇒  🔂  industry-wide uptake ⇒ 🗑 old status quo into the dustbin  

https://lnkd.in/gXxKVmp8

New post by CEO Charles Fisher addresses a question we're often asked: "What is the FDA's stance on using AI-generated digital twins of clinical trial participants in clinical trials?"

https://lnkd.in/g4g5ZKTd

US FDA comments on Unlearn’s PROCOVA methodology

🚀 Unlearn’s name is a portmanteau of UNsupervised LEARNing and we are an #AI company, not a biotech company. 

➡️ Learn why we started Unlearn: https://bit.ly/3RG7JV8

We train AI models, called Digital Twin Generators, for specific disease indications. To scale our solutions across medicine, we’re going to create a universal Digital Twin Generator, a single model for all of human health. 🌐

🤔 Curious how? Read about our Top Secret Plan for #AI in #medicine here: https://bit.ly/46T9F0M

🌐 At Unlearn, we're driven by a set of core beliefs that guide our work and shape our vision for the #future of #medicine. These beliefs form the foundation of our commitment to harnessing the power of #AI to revolutionize medicine and transform the lives of millions of people worldwide. 

🚀 Want to know how we’re using AI to reinvent the future of medicine? Read our blog: https://bit.ly/47SYsyz

Most #ClinicalTrial participants have one chance at participating in a trial and receiving an experimental treatment that may help them. When participants are randomized to a placebo group, they unknowingly lose that opportunity. 

At Unlearn, we’ve built a novel type of randomized controlled trial design, TwinRCT, which uses #DigitalTwins of clinical trial participants to allow sponsors to safely improve the #power and #speed of their clinical trials. 🚀

Learn how: https://bit.ly/4aegAEu

Ready to redefine what’s possible? Join us at Unlearn, where we’re not just changing the game, but rewriting the rules. 🚀 

Check out our open roles: https://bit.ly/3RJnE5b

“There’s these new technologies for trial execution, and as a community, we have a responsibility to embrace these opportunities and incorporate them into our work so that we can get to more effective outcomes. The big benefit is that we can maybe do things smaller and more efficiently. And we need that because there’s so much more work to do. The ecosystem at the moment doesn’t sustain the way we’ve been doing it traditionally. And (Unlearn) is at the leading edge of this thinking.” 

- Kasper Roet, CEO of QurAlis, shared his thoughts at #CNSSummit2023 on pharma's responsibility to embrace #AI in clinical development and how our AI-generated trial participants' digital twins are leading the way. 🚀 

Streaming now: https://bit.ly/4adS1rC

🌐 This #CrohnsDiseaseAwareness week, we’re shedding light on how AI can help overcome some of the biggest challenges in Crohn’s Disease (CD) clinical development. CD is a chronic disease causing inflammation and gastrointestinal tract irritation. Although several drug classes have been developed to combat CD, an estimated 30-40% of patients do not respond to existing therapies or experience relapses. And while the number of CD trials has increased, patient recruitment is a major obstacle.

Enter our CD Digital Twin Generator 1.0 into the clinical trial arena. Our CD DTG 1.0 enables clinical trials with fewer patients, accelerating clinical development and helping to bring new treatments to patients sooner: https://bit.ly/3uJemwR

#AI #Innovation #CrohnsDisease

Domain Not Resolving

DNSSEC

Font Awesome

Common Name Invalid

Amazon S3 CDN

Amazon SSL

Digital Ocean

Next.js

Hetzner

Material-UI

Founder

Aaron Smith

Founder and CEO

Charles Fisher

Graham Siegel

Information Technology

Jonathan Walsh

Vice President of Technology

Alex Lang

Director of Business Development

Denis Wilson

Sales and Support

Luis Olmos

Director of Engineering and Operations

Rajeev Nanda

Head of People

Sana Hafeez

Director, Business Development

Tina T.

Francisco Gimenez

Dylan M. Morris

Mira Murati

Founder & CEO

Director of Board of Directors

United States Companies With Less Than $1B in Revenue (Top 10K)

San Francisco Bay Area Companies With More Than 10 Employees (Top 10K)

Companies With Less Than $500M in Revenue (Top 10K)

Companies With More Than $1M in Revenue (Top 10K)

Unlearn.AI is a biotech AI company that develops a digital twin service for clinical trials. Digital twins enhance healthcare by assessing health risks before a disease manifests its symptoms, according to some experts.  Unlearn brings together a world-class team of experts across pharma, medtech, machine learning, and business who share a vision of using machine learning and biostatistics to improve clinical trials for the benefit of patients and sponsors.

Unlearn invented their TwinRCT solution to enable biopharma partners to run faster, more successful clinical trials. A TwinRCT is a randomized trial that uses machine learning to achieve a higher probability of success with a smaller number of patients. As in a traditional RCT, patients are randomized to a treatment group and a control group, but, unlike a traditional trial, a prognostic digital twin is created for every patient using a machine learning model trained on historical data. The treatment effects for the primary and secondary outcomes can all be estimated from the trial with greater precision after correcting for a prognostic score derived for each patient's digital twin.

TwinRCTs provide a scientifically-sound method for using deep learning and historical patient data to improve clinical trials.

Altimeter Capital

Series C - Unlearn.AI

Venture Round - Unlearn.AI

Series B - Unlearn.AI

Series A - Unlearn.AI

Seed Round - Unlearn.AI

Pre Seed Round - Unlearn.AI

Computer and Software Services and Scientific Services

San Francisco

California

United States

North America

Unlearn Announces Leadership Transition to Accelerate Commercial Growth and AI Innovation

Unlearn Publishes Peer-Reviewed Article Evidencing the Path to Applying AI-Powered Digital Twins in Healthcare

Unlearn.ai sued by big pharma investor in trade secrets dispute

Unlearn.ai sued by big pharma investor in trade secrets dispute - San Francisco Business Times

Steven Herne Joins Unlearn's Executive Team as Chief Commercial Officer

Steven Herne Joins Unlearn’s Executive Team as Chief Commercial Officer

Randomized controlled trials enhanced with AI-generated digital twins to increase trial efficiency and power.

AI models trained on patient-level data to predict individual health outcomes over time.

Support for navigating regulatory landscapes and ensuring TwinRCTs meet FDA and EMA guidelines.

A methodology that uses prognostic scores from digital twins to enhance the statistical power of clinical trials.

India

Asia

Canada

Argentina

South America

Germany

Europe

HTML5

Google Analytics

Google Drive

Fonts.com

Adobe Fonts

jQuery

Office 365

Google Tag Manager

Google Fonts

Vimeo

Provider of an innovative clinical trial management solution for patients

LyfeScience

Deciphex

My Intelligent Machines

Genesis Therapeutics

Deep 6 AI

AiCure

ConcertAI

Flatiron

Cytel

Medidata

Trials.ai

BullFrog AI

Aitia

Perceiv AI

Unlearn is a company focused on AI-powered clinical trials, utilizing digital twins of patients to design more efficient, ethical, and reliable clinical studies. They aim to improve treatment comparisons and personalized treatment plans using AI, with the goal of scaling these solutions to turn most of medicine into a computational science.

news impact assignment basic	general	Feb 15, 2024 10:55 PM	431a330e
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Feb 15, 2024 10:55 PM	25ac9578
company summary	general
signals	general	Feb 15, 2024 10:55 PM	bf4c1e7f
crunchbase trigger	general	Nov 22, 2024 7:44 AM	91dcba09
crunchbase profile	general	Nov 22, 2024 9:26 AM	3e3d388c
li profile	general	Feb 15, 2024 10:55 PM	fc080066
translate crunchbase fundingrounds	general	Nov 22, 2024 1:52 PM	58c5c456
peers	general	Feb 15, 2024 10:55 PM	a1f8c2e5
news basic	general	Feb 15, 2024 10:55 PM	005d9977
bundesanzeiger	filings	Feb 15, 2024 10:55 PM	0477d52d
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

AI:UNLEARN

Unlearn